Type One Diabetes Clinical Trial
Type 1 diabetes is caused by an autoimmune process resulting in a selective destruction of
the pancreatic insulin-secreting beta-cell. DiaPep277® is a small, lyophilized powder
containing 24 Amino-acids. We have proved in former studies that DiaPep277® can slow down
beta cells destruction in the pancreas and therefore decelerate the progress of Diabetes.
The objective of the study is to assess the efficacy and safety of administrating DiaPep277®
in type 1 diabetes patients.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT02380339 -
A Combined Biofeedback-virtual Reality System for Reduction of Fear of Hypoglycemia
|
N/A |